Hale Akpınar

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Clinical Characteristics of Inflammatory Bowel Disease in Turkey

Nurdan Tözün, Özlen Atuğ, Neşe İmeryüz et al. · Journal of Clinical Gastroenterology · 2008 · 74 citations

Comparison of High Resolution Magnifying Endoscopy and Standard Videoendoscopy for the Diagnosis of <i>Helicobacter pylori</i> Gastritis in Routine Clinical Practice: A Prospective Study

Can Gönen, İlkay Şımşek, Sülen Sarıoğlu et al. · Helicobacter · 2009 · 65 citations

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 62 citations · Full text

Placebo-controlled Induction, Gastroenterology, Pathology +6

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 61 citations

Urology, Moxibustion, Gastroenterology +6